New Drug Candidate for Methicillin-Resistant Staphylococcus Aureus Bacterial Infection and Other Drug Resistant Bacteria

Back to all technologies
Download as PDF
Researchers at Purdue University have developed new drug candidates to treat Methicillin-resistant Staphylococcus aureus (MRSA)-related bacterial infection. MRSA-related infections are reaching a level of critical concern according to the Centers for Disease Control and Prevention. Purdue researchers have synthesized a line of 187 potential drug candidates, several of which exhibit excellent antimicrobial activity. Through in vitro against MRSA, vancomycin-resistant Staphylococcus aureus (VRSA), vancomycin-resistant Enterococcus faecalis and Enterococcus faecium (VRE), or Streptococcus pneumoniae in a human skin cells infection model, the new drug candidates showed no signs of cytotoxicity, and the skin cells maintained viability between 65-100%. Purdue researchers optimized these new antibacterial drug candidates and achieved a minimum inhibitory concentration between 3.0-5.2 micromolar against different bacterial strains and eliminated 98-99% of bacteria in two hours whereas the current treatment, vancomycin, requires twelve hours.

-Effective Against Drug Resistant Bacterial Strains
-Safe in Mammalian Cells

Potential Applications
-Antibacterial Drug Development

Recent Publication:
"Beta-,gamma-Diaryl alpha-methylene-gamma-butyrolactones as potent antibacterials against methicillin-resistant Staphylococcus aureus"
Elsevier Journal of Bioorganic Chemistry
DOI: 10.1016/j.bioorg.2020.104183
Apr 2, 2021
Utility Patent
United States

Apr 9, 2020
United States
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486